NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair
NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
NRG Therapeutics Announces International Scientific Advisory Board
NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
STEVENAGE, England, Nov. 9, 2022 /PRNewswire/ -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, today announced the closing of a £16 million Series A financing, led by Omega Funds and joined by additional new investor Brandon Capital and founding investor the Parkinson's Virtual Biotech. In connection with the financing, Omega Funds Managing Director Claudio Nessi and Partner Francesco Draetta, as well as Brandon Capital Partner Jonathan Tobin, have joined the company's Board of Directors.
A £16 million Series A financing – led by Omega Funds – has been announced by the innovative neuroscience company NRG Therapeutics Ltd., for the purpose of advancing disease-modifying oral medicines for debilitating chronic neurodegenerative disorders, by enabling investigational new drugs (IND) studies.